2022
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, Almiron M, de Oliveira RD, Cummings DAT, Dean NE, Andrews JR, Ko AI, Croda J. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications 2022, 13: 5536. PMID: 36202800, PMCID: PMC9537178, DOI: 10.1038/s41467-022-33169-0.Peer-Reviewed Original ResearchBiannual and Quarterly Comparison Analysis of Agglutinating Antibody Kinetics on a Subcohort of Individuals Exposed to Leptospira interrogans in Salvador, Brazil
Cruz J, Nery N, Sacramento G, Victoriano R, Montenegro A, Santana J, Costa F, Ko A, Reis M, Wunder E. Biannual and Quarterly Comparison Analysis of Agglutinating Antibody Kinetics on a Subcohort of Individuals Exposed to Leptospira interrogans in Salvador, Brazil. Frontiers In Medicine 2022, 9: 862378. PMID: 35492362, PMCID: PMC9048256, DOI: 10.3389/fmed.2022.862378.Peer-Reviewed Original ResearchMicroscopic agglutination testAntibody kineticsEndemic areasReinfection eventsSubcohort of individualsBurden of leptospirosisLife-threatening diseaseProspective cohortClinical manifestationsAsymptomatic infectionHumoral responseRisk factorsImmune responseLeptospirosis infectionAgglutination testPaucity of informationSerological surveyLeptospirosisSample collection timeInfectionLeptospira interrogansSubcohortFurther studiesHigh rateDisease
2021
A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus
Wunder EA, Adhikarla H, Hamond C, Bonner K, Liang L, Rodrigues CB, Bisht V, Nally JE, Alt DP, Reis MG, Diggle PJ, Felgner PL, Ko A. A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus. ELife 2021, 10: e64166. PMID: 33496263, PMCID: PMC7837694, DOI: 10.7554/elife.64166.Peer-Reviewed Original ResearchConceptsCross-protective immunityPathogenic Leptospira speciesTerms of morbidityLeptospira speciesTransient bacteremiaSingle doseAntibody responseImmune responseApplicable vaccinesVaccine candidatesAnimal modelsEffective preventionAttenuated mutantsZoonotic diseaseLeptospira genusPotential correlatesDisease transmissionDiseaseLeptospirosisImmunityBacteremiaMorbidityImmunizationVaccineRelevant proteinsKnowledge, Attitude, and Practices regarding Leptospirosis among Visitors to a Recreational Forest in Malaysia
Shafie NJ, Halim N, Zalipah M, Amin N, Esa S, Md-Nor S, Casanovas-Massana A, Ko AI, Palma F, Souza F, Costa F. Knowledge, Attitude, and Practices regarding Leptospirosis among Visitors to a Recreational Forest in Malaysia. American Journal Of Tropical Medicine And Hygiene 2021, 104: 1290-1296. PMID: 33534768, PMCID: PMC8045624, DOI: 10.4269/ajtmh.20-0306.Peer-Reviewed Original ResearchConceptsHigh-risk groupPractice scoresWorldwide public health problemCross-sectional studyPublic health problemHigher practice scoresHigher knowledge scoresAppropriate prevention programsGood practice habitsHigh riskHealth problemsKnowledge scorePrevention programsPractice habitsLeptospirosisMajority of respondentsLeptospirosis transmissionMajor causeDiseaseTransmission routesZoonotic diseaseHigher knowledgePotential outbreaksScoresFinal modelCutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators
Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, Casanovas-Massana A, Minasyan M, Farhadian S, Ko AI, Team Y, Dela Cruz CS, Bosio CM. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. The Journal Of Immunology 2021, 206: ji2001025. PMID: 33277388, PMCID: PMC7962598, DOI: 10.4049/jimmunol.2001025.Peer-Reviewed Original ResearchConceptsLipid mediatorsRisk factorsSevere diseaseSevere SARS-CoV-2 infectionHospitalized COVID-19 patientsSARS-CoV-2 infectionImportant immune regulatory roleSevere COVID-19COVID-19 patientsImmune regulatory roleProinflammatory lipid mediatorsCOVID-19Immunomodulatory eicosanoidsImmune mediatorsSerum lipidomeAdvanced agePatientsCOVID-19 pandemicCytochrome P450MortalityDiseaseDysregulationMediatorsLMS productsLipidome
2006
Frequency of antiphospholipid antibodies in patients with infectious diseases using three different ELISA methods
Santiago M, Martinelli R, Reis M, Reis E, Ko A, Fontes R, Silva M, Nascimento E, Espinola R, Harris N, Gharavi A, Pierangeli S. Frequency of antiphospholipid antibodies in patients with infectious diseases using three different ELISA methods. Jornal Brasileiro De Patologia E Medicina Laboratorial 2006, 42: 13-17. DOI: 10.1590/s1676-24442006000100004.Peer-Reviewed Original ResearchEnzyme-linked immunosorbent assayStandard enzyme-linked immunosorbent assayAntiphospholipid syndromeELISA kitInfectious diseasesAntiphospholipid antibodiesKala-azarACL ELISASera of patientsFrequency of positivityCases of leptospirosisCases of syphilisDetection of antibodiesAnticardiolipin antibodiesIgG aPLIgM aPLVisceral leishmaniasisELISA techniquePatientsHigh specificityELISA methodImmunosorbent assayDiseaseDiagnostic specificityGp I